Janssen-Cilag, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), announced on Wednesday that National Health Service (NHS) England would provide funding for its new HIV-1 treatment.
Rezolsta is a once-daily, fixed-combination of darunavir and cobicistat, indicated for use in combination with other antiretroviral medications.
The NHS backing means that across England, clinicians will be able to routinely prescribe darunavir – the UK's most prescribed protease inhibitor – combined with a booster – in only one tablet, to adults living with HIV-1.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze